CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
Breast Cancer, Colorectal Cancer, Lung Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring stage III colon cancer, stage IV colon cancer, stage IV breast cancer, stage IIIA breast cancer, recurrent breast cancer, stage IIIB breast cancer, recurrent non-small cell lung cancer, stage II pancreatic cancer, stage III pancreatic cancer, recurrent pancreatic cancer, recurrent colon cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, duct cell adenocarcinoma of the pancreas, stage IV pancreatic cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or inoperable non-small cell lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas Bidimensionally measurable lesions that are not previously irradiated New lesions that have developed in a previously irradiated field may be used as measurable disease No brain metastases Patients with prior brain metastases are allowed provided they have undergone prior resection of metastases and/or 1 prior course of cranial irradiation, have no new sites of brain metastases since then, have no worsening CNS symptoms, and have discontinued prior corticosteroids for at least 30 days Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Not specified Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST or ALT no greater than 2 times ULN (5 times ULN if due to liver involvement) Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 30 days after study participation Capable of swallowing intact study medication capsules Capable of following instructions regarding study medication or has daily caregiver to administer study medication No concurrent serious infection No life-threatening illness unrelated to tumor No other prior or concurrent malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior immunotherapy or biologic therapy Chemotherapy: At least 4 weeks since prior cytotoxic chemotherapy No more than 1 prior cytotoxic chemotherapy regimen for metastatic non-small cell lung or colon cancer No more than 2 prior cytotoxic chemotherapy regimens for breast cancer No prior cytotoxic chemotherapy for pancreatic cancer Endocrine therapy: See Disease Characteristics At least 2 weeks since other prior hormonal therapy Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery: See Disease Characteristics Other: No other concurrent anticancer agents
Sites / Locations
- University of Alabama at Birmingham Comprehensive Cancer Center